Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of reslizumab in eosinophilic asthma
2010-024540-15Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reslizumab in eosinophilic asthma (EA), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Long-term safety of reslizumab. Started May 2011; status: completed.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2010-024540-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024540-15.